GH Research PLC Ordinary Shares (GHRS) Stock Price

GHRSStock
$28.92+114.83%52W
Market Cap$1.99B
P/E
PEG Ratio
Div yield
Beta1.36

GHRS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)63.29%
Price vs S&P 500 (4W)-2.55%
VGM Score72.55

GHRS Earnings Surprise History

Q2 25-0.15est. -0.20
Q3 25-0.23est. -0.23
Q4 25-0.22est. -0.27
Q1 26-0.31est. -0.26
Q2 26-0.23est. -0.30

GHRS Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.20
4.20
4.25
4.24

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
GHRSGH Research PLC Ordinary Shares
B$28.92
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About GH Research PLC Ordinary Shares

GH Research PLC is a clinical-stage biopharmaceutical company developing novel mebufotenin-based therapies for treatment-resistant depression. The company's pipeline includes two proprietary candidates: GH001, an inhalable formulation, and GH002, an intravenous formulation. GH Research is focused on addressing a significant unmet medical need in depression treatment through its dedicated R&D operations.